Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11526 posts found.

800px-industria_novartis_1

Novartis announces positive Phase 2 data of rare renal disease therapy iptacopan

October 26, 2020 Sales and Marketing

Novartis has announced positive Phase 2 interim analysis results for iptacopan, which is an investigational oral treatment for rare renal …
News
706px-fentanyl_lollipops_actiq_400_mcg

UK Government outlines steps to tackle growing misuse of fentanyl

October 26, 2020 Sales and Marketing

The British Government has responded to a report investigating the misuse of fentanyl and painkillers in the UK. In January …
News
800px-who_flag_2

WHO warns regulators to consider all available evidence before approving remdesivir for COVID-19

October 26, 2020 Sales and Marketing COVID, COVID-19, Gilead, coronavirus

The World Health Organization’s Chief Scientist Soumya Swaminathan has warned that experts and regulators assessing the use of Gilead’s remdesivir …
News
me_and_calcin_at_aquarium_usa

Patient Experience: Living with Timothy syndrome

October 26, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Timoty syndrome, feature, patient experience, rare disease

Thirteen-year-old Calvin Muir lives with the ultra-rare genetic condition Timothy syndrome. Like many parents of rare disease patients, his mother …
Feature
fdaoutsideweb

FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients

October 23, 2020 Medical Communications, Sales and Marketing COVID-19, FDA, Gilead, remdesivir

The FDA has approved Gilead’s antiviral therapy Veklury (remdesivir) for the treatment of hospitalised COVID-19 patients, making it the first …
News
nice_new_london_office_internal_3_web

Bayer’s Nubeqa secures NICE recommendation for hormone-relapsed prostate cancer at risk of metastasis

October 23, 2020 Medical Communications, Sales and Marketing Bayer, NCIE, Nubeqa, pharma

NICE has given its recommendation to Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for …
News
merck-keytruda

NICE recommends MSD’s Keytruda for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

October 22, 2020 Sales and Marketing MSD, NCIE, NHS, keytruda

NICE has moved to recommend the use of MSD’s blockbuster immunotherapy drug Keytruda (pembrolizumab) as a monotherapy in the treatment …
News
astrazeneca-sign

FDA grants priority review to AstraZeneca’s Tagrisso as an adjuvant for early-stage EGFR-mutated non-small cell lung cancer

October 20, 2020 Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Tagrisso

The FDA has revealed its decision to grant Priority Review to AstraZeneca’s Tagrisso (osimertinib) as an adjuvant treatment of patients …
News
shutterstock_3

EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma

October 20, 2020 Manufacturing and Production, Sales and Marketing CAR T, CAR-T, CHMP, EMA, kite pharma, lymphoma

Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received positive recommendation from the EMA’s …
News
eu_member_flags

European Commission stands by €1bn remdesivir supply deal despite disappointing COVID-19 benefit

October 19, 2020 Manufacturing and Production, Sales and Marketing COVID-19, Europe, Gilead, remdesivir

As Europe continues to face down a rising second wave of COVID-19, the European Commission quickly moved to secure a …
News

Pfizer won’t apply for COVID-19 vaccine emergency authorisation until after US election, CEO says

October 19, 2020 Sales and Marketing COVID-19, Pfizer, US, Vaccine

The Chief Executive Officer of Pfizer has said that the company will now submit their vaccine for FDA Emergency Use …
News
brexit-hintergrund_web

UK life sciences industry does not want no-deal Brexit, says ABPI Chief

October 19, 2020 Sales and Marketing ABPI, EU, UK, brexit, pharma

Prime Minister Boris Johnson’s sudden change of position that the UK is now expecting a no-deal scenario with the European …
News
sanofi_hq__boetie_hall_web

Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis

October 19, 2020 Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis

Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …
News
janssen_latest_logo_on_sign

CHMP recommendation for Janssen’s Tremfya in active psoriatic arthritis

October 19, 2020 Sales and Marketing CHMP, EMA, Janssen, Tremfya

Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) has scored a recommendation from the EMA’s Committee for Medicinal Products for Human Use …
News

FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal

October 19, 2020 Sales and Marketing AbbVie, FDA, Roche, Venclexta, pharma

The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose …
News
The Gateway to Local Adoption Series

Latest content

Sandoz launches allergy relief nasal spray in Germany and Switzerland

April 9, 2026

Japan approve Daiichi Sankyo’s Enhertu as a second-line treatment for gastric cancer

April 9, 2026

Trelleborg to take part in Medtec Japan 2026

April 8, 2026

Kainova Therapeutics expands phase I/II trial of antibody drug

April 7, 2026

Eisai starts enrolment for phase 2 narcolepsy study evaluating E2086

April 7, 2026